Semnur Pharmaceuticals, Inc. SEC filings SMNRW
Semnur Pharmaceuticals, Inc. has 221 filings in SEC EDGAR's recent list, going back to Mar 1, 2022. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Jul 7, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 7, 2026 | Jul 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Agreement ended
|
Apr 23, 2026 | Apr 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Mar 17, 2026 | Mar 13, 2026 |
| 8-K |
Current report
Other events
|
Dec 3, 2025 | Dec 3, 2025 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Sep 26, 2025 | Sep 22, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Sep 4, 2025 | Sep 3, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 22, 2025 | Aug 20, 2025 |
| 8-K |
Current report
Other events
|
Aug 11, 2025 | Aug 11, 2025 |
| 8-K |
Current report
Material agreement
|
Jul 28, 2025 | Jul 22, 2025 |
| 8-K |
Current report
Other events
|
Jul 11, 2025 | Jul 11, 2025 |
| 8-K |
Current report
Other events
|
Jun 12, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Other events
|
May 12, 2025 | May 9, 2025 |
| 8-K |
Current report
Material agreement
|
Apr 22, 2025 | Apr 16, 2025 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Apr 16, 2025 | Apr 11, 2025 |
| 8-K |
Current report
Listing notice
|
Apr 9, 2025 | Apr 2, 2025 |
| 8-K |
Current report
Other events
|
Mar 12, 2025 | Mar 11, 2025 |
| 8-K |
Current report
Other events
|
Feb 11, 2025 | Feb 11, 2025 |
| 8-K |
Current report
Other events
|
Jan 8, 2025 | Jan 8, 2025 |
| 8-K |
Current report
Other events
|
Dec 11, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Other events
|
Nov 12, 2024 | Nov 11, 2024 |
| 8-K |
Current report
Other events
|
Oct 11, 2024 | Oct 11, 2024 |
| 8-K |
Current report
Listing notice
|
Oct 7, 2024 | Oct 2, 2024 |
| 8-K |
Current report
Other events
|
Sep 12, 2024 | Sep 11, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 5, 2024 | Aug 30, 2024 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Aug 9, 2024 | Aug 9, 2024 |
| 8-K |
Current report
Auditor change
|
Jul 17, 2024 | Jul 15, 2024 |
| 8-K |
Current report
Material agreement, New debt, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Jul 10, 2024 | Jul 10, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 5, 2024 | Jul 2, 2024 |
| 8-K |
Current report
Agreement ended, Regulation FD disclosure
|
Jun 27, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Listing notice
|
Feb 27, 2024 | Feb 22, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jan 10, 2024 | Jan 9, 2024 |
| 8-K |
Current report
Other events
|
Dec 29, 2023 | Dec 29, 2023 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 20, 2023 | Nov 17, 2023 |
| 8-K |
Current report
Material agreement, New debt, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 11, 2023 | Oct 11, 2023 |
| 8-K |
Current report
Other events
|
Aug 30, 2023 | Aug 29, 2023 |
| 8-K |
Current report
Material agreement
|
Aug 28, 2023 | Aug 23, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 4, 2023 | Aug 4, 2023 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Jul 13, 2023 | Jul 13, 2023 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Apr 12, 2023 | Apr 11, 2023 |
| 8-K/A |
Amended current report
Material agreement, Regulation FD disclosure
|
Jan 26, 2023 | Jan 25, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jan 26, 2023 | Jan 25, 2023 |
| 8-K |
Current report
Auditor change
|
Oct 19, 2022 | Oct 14, 2022 |
| 8-K |
Current report
Other events
|
May 27, 2022 | May 26, 2022 |
| 8-K |
Current report
Other events
|
Apr 15, 2022 | Apr 11, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Other events
|
Apr 12, 2022 | Apr 6, 2022 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SMNR (OTC), SMNRW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1913577
- Former names
- Denali Capital Acquisition Corp. (until Sep 23, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.